COronary Native Artery First in Man Investigation of ISA 247 Elution to Prevent Restenotic Mechanisms (CONFIRM 1)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

103 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-06-30

Study Completion Date

2012-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This First In Man study is a prospective, multicentre, single blind, randomized, controlled clinical trial of the CINATRA™ ISA 247 Coated Coronary Stent System as compared to the CINATRA™ Coronary Stent System. The study will enroll up to 100 evaluable patients at up to 7 sites. Clinical follow up will occur at 1 month, 6 months, and 1, 2, 3, 4 and 5 years post procedure. Repeat angiography and IVUS will be performed at the 6 month follow up time point for all subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Clinical Evaluation of the Cinatra™ Corolimus-Eluting Coronary Stent in De Novo Lesions in Native Coronary Arteries

NCT01025869

Coronary Artery Disease

TERMINATED NA

First in Men Study: BIOMAG-I

NCT04157153

Coronary Artery Disease

ACTIVE_NOT_RECRUITING NA

First-in-man Trial Examining the Safety and Efficacy of BuMA Supreme and Resolute Integrity in Patients With de Novo Coronary Artery Stenosis

NCT02236975

Coronary Artery Disease

COMPLETED PHASE2/PHASE3

CVT-ISR First in Human Trial for Coronary In-Stent Restenosis

NCT05731700

In-stent Restenosis

COMPLETED NA

PIONEER III Trial to Assess Safety and Efficacy of the BuMA Supreme™ Drug Coated Coronary Stent in Patients With Coronary Disease

NCT03168776

Coronary Artery Disease

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

This arm will receive the coated stent

Group Type EXPERIMENTAL

CINATRA™ ISA 247 Coated Coronary Stent System

Intervention Type DEVICE

Drug coated cobalt chromium stent implantation

B

This arm will receive a bare metal stent

Group Type ACTIVE_COMPARATOR

CINATRA™ Coronary Stent System

Intervention Type DEVICE

Bare metal cobalt chromium stent implantation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CINATRA™ Coronary Stent System

Bare metal cobalt chromium stent implantation

Intervention Type DEVICE

CINATRA™ ISA 247 Coated Coronary Stent System

Drug coated cobalt chromium stent implantation

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patients with stable angina pectoris (Canadian Cardiovascular Society 1, 2, 3) or unstable angina pectoris with documented ischemia (CCS 4, Braunwald Class IB-C, IIB-C or IIIB-C), or patients with documented silent ischemia.
2. Patients who are eligible for coronary revascularization (percutanous angioplasty).
3. Acceptable candidates for coronary artery bypass grafting (CABG).
4. Patients with de novo lesion in a native coronary artery \>50% and \<100% stenosis.

NOTE: Treatment of lesions in a non-target vessel is up to the investigator's discretion (max. two-vessel-disease).

ONLY a bare metal stent (no drug eluting stent) can be used for this treatment. Treatment of any non-target vessel lesions must be successfully completed before enrolling patient and placing study stent.
5. The target lesion must be a maximum length of 13 mm (visual estimate) and able to be covered by one stent.
6. The reference diameter of the target lesion must be 3.0 mm by visual estimate.
7. Left ventricular ejection fraction of \>30%.
8. Patients willing to provide written informed consent prior to participation and willing and able to participate in all follow-up evaluations.

Exclusion Criteria

1. Patients under the age of 18 or unable to give informed consent.
2. Women who are pregnant. Women of child bearing potential must have a negative pregnancy test within 7 days prior to enrollment and utilize reliable contraception at a minimum until after the angiographic follow up.
3. Patients who previously participated in this study.
4. Patient is currently participating in an investigational drug or device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints.

NOTE: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
5. Life expectancy of less than 12 months or factors making clinical and/or angiographic follow-up difficult (no fixed address, etc.).
6. Patients who intend to have a major surgical intervention within 6 months of enrollment in the study.
7. Patients with new ST elevation within 48 hours prior to stenting.
8. Braunwald Class IA, IIA and IIIA angina pectoris.
9. Patients with a contraindication to an emergency coronary bypass surgery.
10. Patients who had previous Coronary Artery Bypass Surgery (CABG).
11. Any individual who may refuse a blood transfusion.
12. Serum creatinine \>3.0 mg/dL.
13. Platelet count \<100,000 cells/mm³.
14. Patients with intolerance or contraindication to acetylsalicylic acid (aspirin), heparin, cyclosporin or cyclosporine derivative, clopidogrel or ticlopidine drug therapy.
15. Patients with contrast agent hypersensitivity that cannot be adequately pre-medicated.
16. Patients who have a stent anywhere within the target vessel.
17. Any planned interventional treatment of any vessel post study procedure.

18. Patients with previous PCI of the same segment (i.e. no restenotic lesions).
19. Previous interventional procedure (less than 6 months) anywhere within the target vessel;
20. Target lesion is located in or supplied by an arterial or venous bypass graft.
21. Target lesion involves a side branch \>2.0mm in diameter.
22. Ostial target lesion (within 3.0mm of vessel origin).
23. Target vessel has evidence of thrombus or is excessively tortuous that makes it unsuitable for proper stent delivery and deployment .
24. Patients with total occlusions (TIMI 0).
25. Significant (\>50%) stenosis proximal or distal to the target lesion that might require revascularization or impede run off.
26. Target lesion requires treatment with a device other than the predilatation balloon prior to stent placement (including but not limited to, directional coronary atherectomy, excimer laser, rotational atherectomy, cutting balloon etc.).

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No